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Background: Reproductive factors influence the risk of developing epithelial ovarian cancer (EOC), but little is known about their
association with survival. We tested whether prediagnostic reproductive factors influenced EOC-specific survival among 1025
invasive EOC cases identified in the European Prospective Investigation into Cancer and Nutrition (EPIC) study, which included
521 330 total participants (approximately 370 000 women) aged 25–70 years at recruitment from 1992 to 2000.
Methods: Information on reproductive characteristics was collected at recruitment. Cox proportional hazards regression models
were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), and multivariable models were adjusted for age and
year of diagnosis, body mass index, tumour stage, smoking status and stratified by study centre.
Results: After a mean follow-up of 3.6 years (±3.2 s.d.) following EOC diagnosis, 511 (49.9%) of the 1025 women died from EOC.
We observed a suggestive survival advantage in menopausal hormone therapy (MHT) users (ever vs never use, HR¼ 0.80,
95% CI¼ 0.62–1.03) and a significant survival benefit in long-term MHT users (X5 years use vs never use, HR¼ 0.70, 95%
CI¼ 0.50–0.99, Ptrend¼ 0.04). We observed similar results for MHT use when restricting to serous cases. Other reproductive factors,
including parity, breastfeeding, oral contraceptive use and age at menarche or menopause, were not associated with
EOC-specific mortality risk.
Conclusions: Further studies are warranted to investigate the possible improvement in EOC survival in MHT users.
Ovarian cancer is the seventh most common cause of cancer
mortality among women worldwide and the most lethal gynaeco-
logical malignancy (Allemani et al, 2014). It is well established that
epithelial ovarian cancer (EOC) has a hormonal aetiology as
evidenced by the lower risk of developing EOC among women who
are parous (Riman et al, 2004; Whittemore et al, 1992) or oral
contraceptive (OC) users (Beral et al, 2008; Tsilidis et al, 2011;
Fortner et al, 2015) and the higher EOC risk with use of
menopausal hormone therapy (MHT) (Beral et al, 2015). The
changes in steroid hormone signalling that underlie these risk
associations are complex and little understood; however, in general
it is thought that higher oestrogen levels may promote ovarian
carcinogenesis (Cramer and Welch, 1983; Cunat et al, 2004), while
higher levels of progestins and progesterone may have a protective
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role against EOC (Risch, 1998; Modugno et al, 2012). Given the
association between reproductive factors and EOC incidence, and
its hypothesised hormonal aetiology, it is plausible that reproduc-
tive factors may also influence EOC prognosis.
Patient age and tumour characteristics, such as stage and
histological subtype, are important prognostic factors. For
example, cases diagnosed with the most common (serous)
histological subtype of EOC have a poor prognosis as compared
with other subtypes (endometrioid, mucinous and clear cell)
(Rosen et al, 2009). Epidemiological studies may provide further
insights about the possible links between reproductive factors and
EOC survival while accounting for known clinical prognostic
factors. In a large Australian case–control study including 676 EOC
cases (419 deaths) (Nagle et al, 2008), women who had ever vs
never breastfed had an improved survival, but there was no trend
with breastfeeding duration. In contrast, other studies (Jacobsen
et al, 1993; Kjaerbye-Thygesen et al, 2006; Robbins et al, 2009;
Zhang and Holman, 2012) reported no association with breast-
feeding. In a prospective study of 644 EOC cases (419 deaths) from
a Norwegian breast screening cohort (Jacobsen et al, 1993), an
older age at first birth was associated with worse survival but there
was no apparent trend, and this result was not confirmed by other
studies (Kjaerbye-Thygesen et al, 2006; Nagle et al, 2008; Yang
et al, 2008). Three previous studies (each with X649 EOC cases
identified from population-based case–control studies) investigated
MHT use and observed no influence on survival among all EOC
cases (Mascarenhas et al, 2006; Nagle et al, 2008; Wernli et al,
2008); however, in the two studies that evaluated serous cases, one
reported improved survival in ever vs never users of MHT
(HR¼ 0.69, 95% CI 0.48–0.98) (Mascarenhas et al, 2006), while
there was no association in the other study (Nagle et al, 2008).
Because of the inconsistent findings reported across studies, further
research is needed to assess the possible influence of reproductive
factors on EOC survival. In the current study, we investigated
prediagnostic reproductive characteristics in relation to EOC-
specific survival among EOC cases overall and serous cases in the
European Prospective Investigation into Cancer and Nutrition
(EPIC) study.
MATERIAL AND METHODS
Study population. The study design has been previously detailed
(Riboli et al, 2002). In brief, the EPIC cohort includes 4500 000
individuals, of which approximately 370 000 are women. The
participants were mainly recruited from the general population
who resided in 23 study centres in 10 European countries,
Denmark, France, Spain, Germany, The Netherlands, Greece, Italy,
Norway, Sweden and the United Kingdom, between 1992 and
2000. Exceptions to this included: French participants were
recruited through health insurance databases; some members of
the Italian and Spanish cohorts were recruited via local blood
donor registries; some members of the Utrecht and Florence
cohorts were recruited through local breast screening programmes;
and approximately half of the Oxford cohort included individuals
who did not eat meat. Ethics approval for the study was obtained
from the International Agency for Research on Cancer and the
local review boards at the participating centres.
Outcome assessment. According to the improved understanding
of ovarian cancer pathogenesis (Jarboe et al, 2008; Kurman and
Shih, 2011), we defined incident ‘ovarian’ cancer cases using the
International Classification of Disease for Oncology (ICD-O-3)
codes C56.9, C57.0 and C48, including primary peritoneal and
fallopian tube cancers. Cases were identified through linkage with
national cancer registries in Denmark, Italy, The Netherlands,
Norway, Spain, Sweden and the UK. In France, Germany and
Greece, cases were identified using insurance records, cancer
registries and active follow-up of participants. Data on tumour
invasiveness, histology, stage and grade were available from cancer
registries and a pathology record review. Information on vital
status, the causes and dates of death were obtained using record
linkages with cancer registries, boards of health and death indices
in Denmark, Italy (except Naples), The Netherlands, Norway,
Spain, Sweden and the UK or through active follow-up (inquiries
by mail or telephone to participants, municipal registries, regional
health departments, physicians and hospitals) in Germany, Greece,
Naples (Italy) and France. Causes of death were reported as
specified by the International Statistical Classification of Diseases,
Tenth revision (ICD-10). As different procedures were used to
obtain follow-up data on vital status across the study centres, this
resulted in differences across the centres in the timing to report the
causes of death. To account for this, the follow-up dates were
truncated to when 80% of the causes of death at each centre were
known (June 2005–June 2009) with the following exceptions; in
Greece and Germany, the date of last known contact was the date
of censoring and this extended to November 2009 for Greece and
February 2010 for Germany. Data were unavailable to examine
recurrent EOC in the current study.
We identified 1405 ovarian cancer cases and the following
exclusions were used: not first incident (n¼ 60); non-epithelial
cancer or unknown histology (n¼ 95); missing date of death
(n¼ 4); unknown vital status (n¼ 2); ovarian cancer diagnosed
after the vital status censoring date (n¼ 84); date of diagnosis was
the same as date of death (n¼ 6); missing extensive information on
reproductive history, specifically age at menarche, number and age
at first full term pregnancy (FTP), OC use and breastfeeding
duration (n¼ 28); borderline EOC cases (n¼ 99); tumours missing
invasiveness (n¼ 2); leaving 1025 invasive EOCs in the current
analysis. The outcome of interest was death from EOC or an EOC-
related cause, defined as death owing to possible metastatic
tumours, including peritoneum not otherwise specified (NOS),
specified parts of the peritoneum, fallopian tube, corpus uteri and
uterus NOS. Of the n¼ 554 total deaths that were observed, an
EOC-specific death was recorded for n¼ 511 (92%) and deaths
that occurred owing to other causes (n¼ 43) were censored.
Exposure assessment. At the time of study recruitment, partici-
pants completed questionnaires on reproductive history, diet and
lifestyle. Data collection procedures were centralised as a single
study with multiple centres. Reproductive variables that were
investigated included parity (live births and still births only;
number and age at first FTP), ever breastfed and duration, OC use
and duration, age at menarche and menopause, hysterectomy and
total ovulatory lifespan. For the MHT variables (assessed at
recruitment), participants were asked if they had ever used MHT,
the timing of use (whether they were current users), their age at
start and total duration of use. The duration of MHT use refers to
the total duration for the former users or the duration up until the
time of recruitment among the current users. Information on MHT
formulation was only available from women who reported that
they were currently using MHT at recruitment. Information on the
time since last MHT use was unavailable. Menopausal status was
defined using information on menstruation status, hysterectomy,
oophorectomy, use of exogenous hormones and age as detailed
previously (Lahmann et al, 2004). Breastfeeding duration was only
available for the first three and the last FTP, therefore for women
reporting 44 FTPs the duration was estimated as the number of
pregnancies multiplied by the mean duration of breastfeeding per
child. The total ovulatory lifespan was calculated as the difference
between a participant’s age at menopause and their age at menarche
(postmenopausal) or the difference between their age at recruitment
and age at menarche (premenopausal, perimenopausal), less the time
that she was pregnant, calculated as the number of FTPs multiplied by
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0.75 (equivalent to 9 months), and/or used OCs. Data on tubal
ligation, family history of ovarian cancer and BRCA1/2 status were
not available for any of the cases. Age at last FTP was not assessed
because this information was unknown for 88% of the parous cases
and family history of breast cancer was not examined as a confounder
because this information was missing for 56% of the cases.
Statistical analysis. Hazard ratios (HRs) and 95% confidence
intervals (CIs) were calculated using Cox proportional hazards
regression models. Person-time was calculated as the number of
days between EOC diagnosis and the date of death, emigration, loss
to follow-up or censoring, whichever occurred first. Multivariable
models were adjusted for covariates that were selected a priori
because of their known influence on risk of EOC death; age at
diagnosis (continuous), BMI (o23 kgm 2, X23–o25 (refer-
ence), X25–o30, X30), tumour stage (local (reference), regional,
metastatic, unknown) and smoking status (never (reference),
former, current, unknown). We further adjusted for the year of
diagnosis (continuous) to account for possible changes in the
treatment regime for ovarian cancer over time. All models were
stratified by study centre. We tested whether additional adjustment
for the following potential confounders (education level, marital
status, physical activity and alcohol intake) or tumour character-
istics (histologic subtype and grade) changed the risk estimates by
X10% (Greenland, 1989), but the risk estimates were very similar
therefore none of these factors were included in the final models.
Other than education level, additional measures of social class were
not available in this study. The Ptrend was calculated by entering
continuous terms into the regression model. Analyses were
conducted using the survival package (Therneau, 2014) in R
version 3.0.2 (R Core Team, 2014). The proportional hazards
assumption was tested using the method described by Grambsch
and Therneau, 1994.
We carried out the following stratified analyses by: age at
diagnosis (o65 years, X65 years), because older women may be
less likely to be offered standard treatments and more likely to
develop toxicity (Tew et al, 2014); BMI (o25 kgm 2,X25 kgm 2)
because obese women may have a decreased survival owing to
surgical complications and/or inadequate chemotherapy dosing
(Modesitt and van Nagell, 2005); histological subtype (serous, non-
serous, including endometrioid, mucinous and clear cell); and
tumour stage (early-stage/FIGO SI/II, late-stage/FIGO SIII (Prat,
2014)). Interaction terms (Pint) between the binary stratifying
variables and the categorical reproductive variables were included in
multivariable models and were compared with models without
interaction terms using the likelihood ratio test. Sensitivity analyses
were carried out after restricting analyses to a uniform subgroup of
cases that were classified as the most common (serous) histological
subtype, cases who were diagnosed with SII/III tumours, cases with
tumours from the ovary (C56.9) only and participants who were
postmenopausal at recruitment. We also examined MHT use
variables after additionally adjusting for hysterectomy status.
Statistical significance was set at Po0.05.
RESULTS
The study population included 1025 women diagnosed with EOC.
The median (range) of the participant ages was 54 years (26, 86)
and 61 years (34, 98) at the baseline questionnaire completion and
at cancer diagnosis, respectively. During a mean follow-up of 3.6
years (±3.2 s.d.), 511 individuals (49.9%) died from ovarian
cancer. Survival analysis of clinical and demographic character-
istics showed that older age, poorly/undifferentiated tumour grade,
advanced stage and current smoking at the study baseline
were associated with a worse EOC-specific survival (Table 1).
Compared with serous cases, women with endometrioid tumours
had a better prognosis (HR¼ 0.53, 95% CI¼ 0.37–0.75), whereas
cases with NOS tumours had a poorer prognosis (HR¼ 1.41, 95%
CI 1.11–1.79).
We investigated reproductive factors that were assessed on
average 5.9 years (±3.4 s.d.) prior to the diagnosis of EOC. In the
Table 1. Association between clinicopathological and




n(%) HRc 95% CI
Age at diagnosisd, years
o50 103 44 (42.7) Ref.
50–59 361 160 (44.3) 1.25 0.88–1.79
60–69 411 218 (53.0) 1.68 1.17–2.41
70þ 150 89 (59.3) 2.58 1.71–3.90
Ptrend o0.001
Tumour site
Ovary 960 482 (50.2) Ref.
Othere 65 29 (44.6) 1.01 0.67–1.53
Histology
Serous 568 298 (52.5) Ref.
Mucinous 74 27 (36.5) 1.16 0.77–1.77
Endometrioid 126 39 (31.0) 0.53 0.37–0.75
Clear cell 49 13 (26.5) 0.82 0.46–1.46
NOS 164 111(67.7) 1.41 1.11–1.79
Otherf 44 23 (52.3) 1.20 0.77–1.90
Gradeg
Well differentiated 64 13 (20.3) Ref.
Moderately differentiated 210 95 (45.2) 1.99 1.07–3.70
Poorly/undifferentiated 345 193 (55.9) 2.41 1.31–4.43
FIGO stageh
Stage I 141 21 (14.9) Ref.
Stage II 78 27 (34.6) 2.77 1.54–4.98
Stage III 300 176 (58.7) 6.34 3.96–10.17
Stage IV 101 61 (60.4) 10.54 6.16–18.03
Stagei
Local 138 18 (13.0) Ref.
Regional 171 62 (36.3) 3.31 1.94–5.64
Metastatic 586 360 (61.4) 8.64 5.32–14.04
Body mass index, kgm2
o23 318 149 (46.9) 0.99 0.76–1.28
23–24.9 235 114 (48.5) Ref.
25–29.9 316 169 (53.5) 1.01 (0.79–1.30)
30þ 156 79 (50.6) 0.85 (0.62–1.16)
Smoking statusj
Never smoker 567 285 (50.3) Ref.
Former smoker 235 113 (48.1) 1.09 (0.86–1.37)
Current smoker 204 104 (51.0) 1.56 (1.22–1.99)
Abbreviations: CI¼ confidence interval; EOC¼epithelial ovarian cancer; FIGO¼
International Federation of Gynecology and Obstetrics; HR¼ hazard ratio; NOS¼not
otherwise specified.
aTotal number of cases n¼ 1025.
bTotal number of fatal cases n¼ 511.
cAdjusted for age at diagnosis (continuous), year of diagnosis (continuous), BMI
(o23 kgm 2, X23–o25 (reference), X25 –o30, X30), tumour stage (local (reference),
regional, metastatic and unknown), smoking status (never (reference), former, current and
unknown) and stratified by study centre.
dAdjusted for all factors mentioned above in footnote c except for age at diagnosis as this
was the variable of interest.
eIncludes fallopian tube and primary peritoneal carcinomas.
fThe ‘other’ histological subtype category included ‘Neoplasm, malignant’ (31.8%),
‘Carcinoma, undifferentiated, NOS’ (25.0%) and ‘Carcinosarcoma, NOS’ (11.4%) and a small
number of ‘Carcinoma, anaplastic, NOS’, ‘Pseudosarcomatous carcinoma, NOS’, ‘Transi-
tional cell carcinoma, NOS’, ‘Solid carcinoma, NOS’, ‘Mullerian mixed tumour’, ‘Meso-
dermal mixed tumour’ and ‘Brenner tumour, malignant’.
gGrade was missing for 39.6% of the cohort.
hFIGO stage was missing for 39.5% of the cohort.
iStage is closely related to FIGO stage but is more complete across the cohort (12.7%
missing).
jSmoking status was missing for 1.9% of the cohort.
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Table 2. Association between prediagnostic reproductive factors and survival among EOC cases overall
Totala Fatal casesb Model 1 Model 2
n n (%) HRc 95% CI HRd 95% CI
Age at menarchee, years
o12 158 83 (52.5) Ref. Ref.
12 187 86 (46.0) 0.89 0.65–1.22 1.01 0.74–1.38
13 253 125 (49.4) 0.91 0.68–1.22 0.84 0.63–1.13
14 223 107 (48.0) 0.84 0.62–1.13 0.75 0.55–1.01
414 186 100 (53.8) 0.93 0.68–1.27 0.90 0.66–1.24
Ptrend 0.76 0.37
Parouse
No 169 86 (50.9) Ref. Ref.
Yes 833 414 (49.7) 0.97 0.77–1.24 0.90 0.71–1.14
Number of FTPse,f
1 159 75 (47.2) Ref. Ref.
2 394 190 (48.2) 1.07 0.81–1.41 1.04 0.78–1.38
3þ 262 142 (54.2) 1.17 0.88–1.57 1.10 0.81–1.49
Ptrend 0.13 0.31
Age at first FTPe,f, years
p20 118 66 (55.9) Ref. Ref.
420–p25 376 167 (44.4) 0.65 0.48–0.87 0.66 0.49–0.90
425–p30 244 125 (51.2) 0.72 0.53–0.99 0.72 0.52–1.00
430 88 52 (59.1) 0.87 0.59–1.26 0.86 0.58–1.28
Ptrend 0.70 0.59
Breastfeedingf,g
Never 120 59 (49.2) Ref. Ref.
Ever 660 327 (49.5) 0.82 0.61–1.11 0.83 0.61–1.12
Duration of breastfeedinge,h, months
p3 205 104 (50.7) Ref. Ref.
43–p6 122 58 (47.5) 0.88 0.62–1.23 1.02 0.71–1.45
46–p12 156 75 (48.1) 0.76 0.55–1.04 0.88 0.63–1.22
412–p24 127 61 (48.0) 0.84 0.60–1.19 0.97 0.68–1.39
424 47 28 (59.6) 1.10 0.69–1.73 1.11 0.69–1.79
Ptrend 0.90 0.87
OC usee
Never 523 273 (52.2) Ref. Ref.
Ever 495 232 (46.9) 1.04 0.86–1.26 0.96 0.79–1.17
Duration of OC usei,j, years
p1 112 45 (40.2) Ref. Ref.
41–p5 164 71 (43.3) 0.88 0.59–1.32 0.98 0.65–1.48
45–p10 101 47 (46.5) 1.12 0.72–1.74 1.26 0.80–1.98
410 77 49 (63.6) 1.69 1.08–2.64 1.74 1.10–2.75
Ptrend 0.006 0.01
Age at menopausek,l, years
p45 89 52 (58.4) 0.94 0.66–1.33 1.06 0.74–1.53
445–p50 207 121(58.5) Ref. Ref.
450–p52 94 50 (53.2) 0.90 0.64–1.27 0.98 0.69–1.40
452 136 77 (56.6) 0.90 0.66–1.22 1.04 0.76–1.41
Ptrend 0.91 0.71
MHT usee,k,m
Never 299 176 (58.9) Ref. Ref.
Ever 233 130 (55.8) 0.85 0.66–1.09 0.80 0.62–1.03
MHT timing of use at baselinee,k,m
Former 69 41 (59.4) 0.94 0.66–1.33 0.85 0.59–1.22
Current 160 88 (55.0) 0.84 0.63–1.12 0.79 0.59–1.06
MHT duration of use at baselinek,m,n, years
o5 121 68 (56.2) 0.99 0.73–1.34 0.95 0.69–1.29
X5 86 49 (57.0) 0.76 0.54–1.07 0.70 0.50–0.99
Ptrend 0.11 0.04
MHT formulation at baseline (current users only)k,m,o
E only 37 24 (64.9) 0.84 0.54–1.31 0.86 0.54–1.35
Eþ P 100 52 (52.0) 0.89 0.62–1.27 0.80 0.55–1.16
Other 12 8 (66.7) 1.08 0.50–2.33 0.92 0.42–2.01
Hysterectomyp
No 831 411 (49.5) Ref. Ref.
Yes 88 45 (51.1) 0.75 0.54–1.04 0.79 0.57–1.10
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analyses of EOC overall, ever vs never OC use was not associated
with EOC-specific survival (HR¼ 0.96, 95% CI¼ 0.79–1.17) but
among OC users a longer duration of use was associated with a
worse survival (410 years vs p1 year of use: HR¼ 1.74 95%
CI¼ 1.10–2.75, Ptrend¼ 0.01; Table 2). Compared with never users
of MHT, long-term users (X5 years vs never users; HR¼ 0.70, 95%
CI¼ 0.50–0.99, Ptrend¼ 0.04) had a better prognosis, and there
was a non-significant improved survival among ever users
(HR¼ 0.80, 95% CI¼ 0.62–1.03). There was no apparent
influence on survival according to the timing of MHT use
(former or current use at the study baseline) or when MHT
formulation was evaluated among current users at baseline. In the
sensitivity analyses of MHT variables when including additional
adjustment for hysterectomy status, we observed similar results to
those reported above (data not shown). In the analyses of age at
first FTP, we observed a better survival among women who
had their first FTP at age 420–p25 years as compared with age
p20 (HR¼ 0.66, 95% CI¼ 0.49–0.90), but there was no
association with the other age at first FTP categories and no
apparent trend (Ptrend¼ 0.59). Finally, there was no association
between other reproductive characteristics (parity, number of
FTPs, ever breastfed or duration, age at menarche or menopause,
hysterectomy or total ovulatory years) and EOC-specific survival.
There were no apparent differences in any of the risk associations
when stratifying by age at diagnosis or BMI (PintX0.07) (data not
shown). When restricting analyses to cases diagnosed with an
ovarian primary tumour (not primary peritoneal or fallopian tube
site), we observed similar results to those reported above (data
not shown).
In the analyses restricted to serous cases, there was little
influence of OC use or duration, or other reproductive factors such
as parity or breastfeeding, on EOC-specific survival (Table 3).
Similar to analyses of EOC overall, we observed better survival
among serous cases who reported an age at first FTP of420–p25
years vs agep20 (HR¼ 0.59, 95% CI¼ 0.38–0.92), but none of the
other age categories were associated with risk, and there was no
evidence of a trend (Ptrend¼ 0.75). Compared with serous cases
who never used MHT, we observed better survival among ever
users of MHT (HR¼ 0.63, 95% CI¼ 0.44–0.90) and a stronger
association with long-term use (X5 years MHT use vs never use,
HR¼ 0.55, 95% CI¼ 0.35–0.87, Ptrend¼ 0.01) and with current,
but not former, use (current MHT use at baseline vs never use,
HR¼ 0.60, 95% CI¼ 0.39–0.90). We carried out exploratory
analyses to compare reproductive factors between serous and
non-serous cases and observed significant heterogeneity in the risk
associations for MHT use and OC duration of use (Pintp0.01)
(Supplementary Table 1). In contrast with the improved survival
observed among serous cases who reported MHT use, there
appeared to be a higher risk of death among non-serous cases who
used MHT. Given that only 23 deaths occurred among 45 non-
serous cases who reported MHT use, this finding should be
interpreted with caution.
In a uniform subgroup of FIGO stage II/III cases (all histological
subtypes), there was no association between OC use or OC
duration of use with EOC-specific survival (Supplementary Table 2).
Compared with never users of MHT, we observed a non-significant
improved survival with ever use of MHT in stage II/III cases
(HR¼ 0.67, 95% CI¼ 0.41–1.08), but there was no trend with
duration of MHT use (Ptrend¼ 0.45). Although based on only 29
stage II/III cases with an early menopause, we observed a worse
survival in women who reported an early age at menopause
(menopause age p45 years vs X45–p50, HR¼ 2.05, 95%
CI¼ 1.04–4.01); this result contrasted with the null association
with menopausal age that was observed in the analyses of EOC
overall and serous cases. We carried out further stratified analyses
to compare risk associations between cases diagnosed with early
stage (FIGO SI/II) vs late stage (FIGO SIII) tumours and observed
no significant heterogeneity (PintX0.06) (data not shown).
In the sensitivity analyses restricted to postmenopausal cases at
recruitment (n¼ 646) whose reproductive exposures were unlikely
to change, we observed similar results to analyses of EOC overall
(Supplementary Table 3). Finally, compared with never users of
MHT (crude analyses), MHT users tended to be younger, had a
slightly lower BMI, were more likely to ever use OCs and used OCs
for a longer duration and a higher proportion were diagnosed with
serous tumours (Supplementary Table 4). There were no
differences for other factors, including tumour grade or stage in
relation to MHT use.
Table 2. ( Continued )
Totala Fatal casesb Model 1 Model 2
n n (%) HRc 95% CI HRd 95% CI
Total ovulatory yearsq
p27.5 212 105 (49.5) Ref. Ref.
427.5–p33.0 207 99 (47.8) 0.87 0.65–1.17 0.91 0.67–1.23
433.0–p36.5 212 94 (44.3) 0.72 0.53–0.96 0.72 0.53–0.97
436.5 194 106 (54.6) 0.87 0.65–1.17 0.97 0.71–1.31
Ptrend 0.04 0.12
Abbreviations: CI¼ confidence interval; EOC¼ epithelial ovarian cancer; FTP¼ full term pregnancy; HR¼ hazard ratio; MHT¼menopausal hormone therapy; OC¼oral contraceptive.
aTotal number of cases n¼ 1025.
bTotal number of fatal cases n¼ 511.
cAdjusted for age at diagnosis (continuous) and stratified by study centre.
dAdjusted for age at diagnosis (continuous), year of diagnosis (continuous), BMI (o23 kgm 2,X23–o25 (reference),X25 –o30,X30), tumour stage (local (reference), regional, metastatic and
unknown), smoking status (never (reference), former, current and unknown) and stratified by study centre.
eMissing for o5% of the cohort.
fAmong parous women only.
gBreastfeeding was missing for 6.4% of the cohort.
hAmong parous women who had ever breastfed.
iAmong OC users only.
jDuration of OC use was missing for 8.3% of women.
kAmong postmenopausal women only.
lAge at menopause was missing for 18.6% of postmenopausal women.
mParticipants from Greece and Sweden were excluded from this analysis as detailed data on MHT use were unavailable.
nMHT duration was missing for 11.2% of individuals who ever used MHT.
oMHT formulation was missing for 6.9% of individuals who reported current use.
pHysterectomy was missing for 10.3% of the cohort.
qTotal ovulatory years was missing for 19.5% of the cohort.
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Table 3. Association between prediagnostic reproductive factors and survival among serous EOC cases
Totala Fatal casesb Model 1 Model 2
n n (%) HRc 95% CI HRd 95% CI
Age at menarchee, years
o12 84 48 (57.1) Ref. Ref.
12 102 50 (49.0) 0.98 0.64–1.51 1.10 0.71–1.69
13 145 76 (52.4) 0.92 0.62–1.38 0.82 0.55–1.23
14 134 67 (50.0) 0.86 0.58–1.30 0.79 0.52–1.20
414 98 54 (55.1) 1.02 0.66–1.57 0.92 0.59–1.44
Ptrend 0.80 0.69
Parouse
No 86 49 (57.0) Ref. Ref.
Yes 474 245 (51.7) 0.94 0.68–1.30 0.96 0.69–1.33
Number of FTPse,f
1 101 48 (47.5) Ref. Ref.
2 215 109 (50.7) 1.22 0.85–1.76 0.95 0.64–1.39
3þ 148 82 (55.4) 1.47 1.00–2.16 1.10 0.73–1.65
Ptrend 0.05 0.38
Age at first FTPe,f, years
p20 61 31 (50.8) Ref. Ref.
420–p25 208 94 (45.2) 0.68 0.44–1.04 0.59 0.38–0.92
425–p30 145 83 (57.2) 0.82 0.53–1.28 0.75 0.47–1.20
430 56 35 (62.5) 0.76 0.45–1.28 0.71 0.40–1.23
Ptrend 0.65 0.75
Breastfeedingf,g
Never 69 34 (49.3) Ref. Ref.
Ever 376 192 (51.1) 0.88 0.59–1.31 0.92 0.61–1.38
Duration of breastfeedingh, years
p3 130 65 (50.0) Ref. Ref.
43–p6 75 39 (52.0) 1.05 0.68–1.61 1.07 0.68–1.69
46–p12 75 33 (44.0) 0.61 0.38–0.98 0.60 0.37–0.99
412–p24 69 38 (55.1) 0.93 0.59–1.45 0.90 0.56–1.43
424 27 17 (63.0) 1.12 0.62–2.02 1.13 0.61–2.08
Ptrend 0.59 0.48
OC usee
Never 275 148 (53.8) Ref. Ref.
Ever 289 147 (50.9) 1.01 0.78–1.31 0.95 0.73–1.23
Duration of OC usei,j, years
p1 67 30 (44.8) Ref. Ref.
41–p5 94 50 (53.2) 0.96 0.58–1.60 1.05 0.61–1.78
45–p10 58 26 (44.8) 0.92 0.52–1.64 1.15 0.63–2.12
410 46 28 (60.9) 1.42 0.80–2.51 1.31 0.71–2.40
Ptrend 0.31 0.42
Age at menopausek,l
p45 52 33 (63.5) 1.26 0.79–2.02 1.38 0.83–2.30
445–p50 112 65 (58.0) Ref. Ref.
450–p52 55 29 (52.7) 0.98 0.61–1.58 0.97 0.58–1.61
452 68 45 (66.2) 1.16 0.77–1.77 1.11 0.71–1.75
Ptrend 0.88 0.64
MHT usee,k,m
Never 151 94 (62.3) Ref. Ref.
Ever 144 80 (55.6) 0.71 0.50–1.00 0.63 0.44–0.90
MHT timing of use at baselinee,k,m
Former 42 25 (59.5) 0.86 0.54–1.38 0.73 0.45–1.18
Current 101 54 (53.5) 0.65 0.44–0.96 0.60 0.39–0.90
MHT duration of use at baselinek,m,n, years
o5 78 43 (55.1) 0.81 0.54–1.22 0.79 0.51–1.21
X5 52 29 (55.8) 0.64 0.41–1.00 0.55 0.35–0.87
Ptrend 0.07 0.01
MHT formulation at baseline (current users only)k,m,o
E only 21 16 (76.2) 0.74 0.41–1.32 0.64 0.34–1.18
Eþ P 65 32 (49.2) 0.63 0.39–1.01 0.61 0.36–1.02
Other 7 3 (42.9) 0.35 0.08–1.53 0.35 0.08–1.50
Hysterectomyp
No 452 231 (51.1) Ref. Ref.
Yes 58 31 (53.4) 0.82 0.55–1.23 0.80 0.53–1.21
Reproductive factors and ovarian cancer-specific survival BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2015.377 1627
DISCUSSION
To our knowledge, the current study was the largest to date to
investigate reproductive factors and EOC-specific survival. In the
analyses of EOC overall, compared with never users of MHT, long-
term MHT users had a better survival and there also was a non-
significant improved survival in ever users of MHT. In contrast,
previous studies of ever vs never use of MHT reported no influence
on survival (Mascarenhas et al, 2006; Nagle et al, 2008; Wernli
et al, 2008; Zhang and Holman, 2012). Similar to earlier studies
(Mascarenhas et al, 2006; Wernli et al, 2008), we observed no
difference in survival according to MHT formulation. Among
serous cases, in comparison with never users of MHT, we observed
a better survival among women who had ever used MHT and
specifically among long-term and current MHT users at the study
baseline. The observation of an improved survival among serous
cases for ever vs never MHT use is consistent with an earlier
Swedish study (Mascarenhas et al, 2006), while the only other
study that investigated serous EOC (Nagle et al, 2008) reported no
association. These results highlight the possibility that MHT use
may have a divergent influence on EOC, wherein MHT users may
have a better survival, which contrasts with the increased risk of
developing incident serous (and endometrioid) EOC based on a
recent meta-analysis of 52 epidemiological studies (Beral et al,
2015). Further studies are needed to investigate MHT use in
relation to survival among serous cases and to extend this analysis
to other individual histological subtypes of EOC as we were unable
to address this issue in the current study owing to the limited
sample size.
Consistent with earlier studies (Kjaerbye-Thygesen et al, 2006;
Nagle et al, 2008; Yang et al, 2008; Robbins et al, 2009; Zhang and
Holman, 2012), we observed that ever use of OCs was not
associated with EOC survival; however, in the current study a
longer duration of OC use among ever users of OCs was
unexpectedly associated with a worse survival. This result
contrasted with two prior reports that observed no influence of
OC duration on EOC survival (Kjaerbye-Thygesen et al, 2006;
Yang et al, 2008). In the current study, there was no association
between OC duration and survival in the analyses restricted to
serous cases. As this was the only report where a longer duration of
OC use was associated with worse survival in EOC overall, this
may be a chance finding.
We noted that the following reproductive factors, namely,
parity, breastfeeding, age at menarche and menopause, hyster-
ectomy and total ovulatory years were not associated with
EOC-specific survival in the analyses of EOC overall or serous
cases. These null associations were consistent with the earlier
Australian study and systematic review of seven studies (Nagle
et al, 2008) and subsequent reports (Yang et al, 2008; Zhang and
Holman, 2012; Robbins et al, 2009), with the following exceptions:
reproductive factors that were associated with a worse survival
included an older age at first delivery (Jacobsen et al, 1993),
younger age at menarche and increasing ovulatory years (Kjaerbye-
Thygesen et al, 2006; Robbins et al, 2009), while breastfeeding was
associated with a better survival (Nagle et al, 2008).
Key strengths of this study include the large number of cases
and the representation of findings from 10 European countries.
Potential limitations of this study were that the exposure data were
collected on average 6 years prior to diagnosis; however, the impact
of this was likely limited for reproductive exposures that occurred
during childbearing years; the majority (63%) of the cases in the
study were postmenopausal at recruitment and had completed
their reproductive history. Furthermore, in sensitivity analyses that
were restricted to postmenopausal women, we observed similar
results to the overall analysis. For MHT, it would have been
informative if follow-up questionnaire data were available to
compare use before and after diagnosis; however, we only had
information on MHT use at recruitment in the current study. Thus
it is possible that some of the current MHT users may have ceased
their use after recruitment, or non-MHT users at baseline might
have subsequently commenced MHT use; these factors would be
expected to attenuate the risk estimates towards the null. We used
a summary staging variable (local, regional, metastatic and
unknown) to adjust for the extent of disease, but data were
unavailable for other prognostic factors such as the amount of
Table 3. ( Continued )
Totala Fatal casesb Model 1 Model 2
n n (%) HRc 95% CI HRd 95% CI
Total ovulatory yearsq
p27.5 119 57 (47.9) Ref. Ref.
427.5–p33.0 117 65 (55.6) 1.34 0.90–1.98 1.33 0.87–2.04
433.0–p36.5 124 55 (47.4) 0.75 0.49–1.13 0.73 0.47–1.13
436.5 101 61 (60.4) 1.22 0.80–1.84 1.22 0.79–1.88
Ptrend 0.74 0.72
Abbreviations: CI¼ confidence interval; EOC¼ epithelial ovarian cancer; FTP¼ full term pregnancy; HR¼ hazard ratio, MHT¼menopausal hormone therapy; OC¼oral contraceptive.
aTotal number of serous cases n¼ 568.
bTotal number of fatal serous cases n¼ 298.
cAdjusted for age at diagnosis (continuous) and stratified by study centre.
dAdjusted for age at diagnosis (continuous), year of diagnosis (continuous), BMI (o23 kgm 2,X23–o25 (reference),X25 –o30,X30), tumour stage (local (reference), regional, metastatic and
unknown), smoking status (never (reference), former, current and unknown) and stratified by study centre.
eMissing for p2.1% of the cohort.
fAmong parous women only.
gBreastfeeding was missing for 6.1% of the cohort.
hAmong parous women who had ever breastfed.
iAmong OC users only.
jDuration of OC use was missing for 8.3% of women.
kAmong postmenopausal women only.
lAge at menopause was missing for 18.5% of postmenopausal women.
mParticipants from Greece and Sweden were excluded from this analysis as detailed data on MHT use were unavailable.
nMHT duration was missing for 9.7% of individuals who ever used MHT.
oMHT formulation was missing for 7.9% of individuals who reported current use.
pHysterectomy was missing for 10.2% of the cohort.
qTotal ovulatory years was missing for 18.8% of the cohort.
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residual disease remaining after surgery and information on
treatment. To account for possible variation in the treatment
offered between the EPIC study centres, we stratified by the study
centre in all the statistical models. As treatment is likely to be
uniform following tumour staging guidelines (Prat, 2014), we
adjusted for stage to account for potential differences in the
treatment received. Finally, as a large number of statistical tests
were performed in this analysis, the significant results may be
chance findings.
In conclusion, in this report from the EPIC study we observed
that most reproductive factors did not appear to influence survival
from EOC. Together with results from the earlier Swedish study
(Mascarenhas et al, 2006), our findings strengthen the evidence for
a possible improvement in survival for serous EOC cases who had
ever used MHT. It will be important to investigate this result
further particularly in relation to the timing of MHT use and to
examine whether MHT use may be associated with survival in
individual non-serous histological subtypes of EOC.
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